4.5 Article

Efficacy, Toxicity, and Pharmacokinetics of Intra-Arterial Chemotherapy Versus Intravenous Chemotherapy for Retinoblastoma in Animal Models and Patients

Journal

TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
Volume 10, Issue 11, Pages -

Publisher

ASSOC RESEARCH VISION OPHTHALMOLOGY INC
DOI: 10.1167/tvst.10.11.10

Keywords

animal models; carboplatin; efficacy; intra-arterial chemotherapy; intravenous chemotherapy; melphalan; ocular tumors; pharmacokinetics; rabbit; retinoblastoma; toxicity

Categories

Funding

  1. National Eye Institute, National Institutes of Health [NIH/NEI K08EY027464]
  2. Knights Templar Eye Foundation
  3. Research to Prevent Blindness Foundation (ABD)
  4. Research to Prevent Blindness
  5. Vanderbilt Ingram Cancer Center Support Grant [CA68485]

Ask authors/readers for more resources

Through controlled comparative rabbit experiments and parallel patient studies, it was found that intra-arterial chemotherapy (IAC) has a higher ocular-to-systemic drug concentration ratio compared to intravenous chemotherapy (IVC), leading to greater efficacy and lower systemic toxicity.
Purpose: Through controlled comparative rabbit experiments and parallel patient studies, our purpose was to understand mechanisms underlying differences in efficacy and toxicity between intra-arterial chemotherapy (IAC) and intravenous chemotherapy (IVC). Methods: In rabbits, ocular tissue drug levels were measured following IAC and IVC. Retinal toxicitywas assessed using electroretinography, fluorescein angiography, optical coherence tomography (OCT) and OCT angiography. Efficacy to eradicate retinoblastoma orthotopic xenografts was compared. In IAC and IVC patients, we measured blood carboplatin pharmacokinetics and compared efficacy and toxicity. Results: In rabbits receiving IAC, maximum carboplatin levels were 134 times greater in retina (P = 0.01) and 411 times greater in vitreous (P < 0.001), and total carboplatin (area under the curve) was 123 times greater in retina (P = 0.005) and 131 times greater in vitreous (P = 0.02) compared with IVC. Melphalan levels were 12 times greater (P = 0.003) in retina and 26 times greater in vitreous (P < 0.001) for IAC. Blood levels were not different. IACmelphalan (but not IVmelphalan or IV carboplatin, etoposide, and vincristine) caused widespread apoptosis in retinoblastoma xenografts but no functional retinal toxicity or cytopenias. In patients, blood levels following IVC were greater (P < 0.001) but, when adjusted for treatment dose, were not statistically different. Per treatment cycle in patients, IVC caused higher rates of anemia (0.32 +/- 0.29 vs. 0.01 +/- 0.04; P = 0.0086), thrombocytopenia (0.5 +/- 0.42 vs. 0.0 +/- 0.0; P = 0.0042), and neutropenia (0.58 +/- 0.3 vs. 0.31 +/- 0.25; P = 0.032) but lower treatment success rates (P = 0.0017). Conclusions: The greater efficacy and lower systemic toxicity with IAC appear to be attributable to the greater ocular-to-systemic drug concentration ratio compared with IVC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available